When you receive a leukopak or processed PBMC shipment, the certificate of analysis is your first and often only window into the quality of what arrived. A good COA gives you enough information to make a release decision, to compare this lot against prior lots, and to trace any downstream assay problems back to starting material variables. A thin COA tells you viability and cell count, which is not enough for any serious cell therapy or immunology research application.
Most leukopak suppliers provide thin COAs. This guide covers what a complete leukopak COA should contain, the difference between RUO and GMP documentation standards, what OrganaBio includes as standard, and what to ask for if your current supplier’s COA is missing critical fields.
Why the COA Matters Beyond Lot Release
The immediate function of a COA is to confirm that the product meets release specifications before you use it. But the COA’s long-term value is as a running dataset. When you can correlate batch-to-batch COA parameters with downstream assay performance, you build a picture of which starting material variables actually predict your experimental outcomes — and you can use that information to tighten your procurement specifications, to identify supplier variability trends, and to flag problematic lots before they enter your workflow.
For cell therapy manufacturing applications, the COA is also a regulatory document. The CMC section of your IND references starting material release criteria and the documentation that demonstrates lots were released against those criteria. A COA that meets GMP documentation standards is part of your regulatory package. A COA that does not is a gap you will need to address before IND submission.
What a Complete Leukopak COA Should Include
Section 1: Product Identification
- Unique lot number. Each collection is a unique lot. The lot number should be traceable back to a specific donor, collection date, collection site, and processing facility.
- Product type and format. Fresh leukopak, processed PBMC (fresh), cryopreserved PBMC, or other format. The format determines the relevant specifications.
- Collection date and processing date. Both dates should be present. The gap between them is the processing timeline. For fresh material, collection and processing dates that are the same day (or show the same day with a documented collection-to-processing time) are a quality signal.
- Collection site and processing facility. For multi-site suppliers, which physical facility processed this lot matters for consistency tracking.
- Intended use designation. Research use only (RUO) or GMP-grade. This designation has regulatory implications for how the material can be used.
Section 2: Donor Information
- Donor ID (anonymized). A coded identifier that allows tracing to the full donor record without revealing PHI. For programs using the same donor across multiple lots, the donor ID enables longitudinal tracking.
- Donor age, sex, and race/ethnicity. These demographics affect immune cell subset composition and are relevant for experimental designs where donor characteristics are a variable.
- ABO blood type. Required for some downstream applications; good to have as standard.
- HLA typing. At minimum HLA-A, B, C, DR, and DQ. Resolution level (low, intermediate, or high) should be specified. KIR genotyping should also appear here for suppliers that provide it.
- Communicable disease testing results. HIV 1/2 Ag/Ab, HBsAg, anti-HBc, HCV Ab or NAT, HTLV I/II, syphilis RPR, CMV IgG/IgM at minimum. Results and test dates should be present, not just a pass/fail summary.
- Donor eligibility determination. For GMP material, a statement confirming that donor eligibility was determined per 21 CFR 1271.75 requirements, with the determination date and the name/qualification of the responsible individual.
Section 3: Collection Parameters
- Anticoagulant used. ACD-A is standard for apheresis; other anticoagulants may be used depending on downstream application requirements.
- Collection volume (mL).
- Pre-collection CBC. Donor CBC at time of collection including WBC, RBC, Hgb, Hct, lymphocyte count, and differential. The pre-collection CBC anchors the product yield and composition expectations.
- Apheresis collection time and blood volume processed.
- Collection-to-processing time. The time elapsed between collection completion and the first processing step. This is one of the most important parameters on the COA for programs where processing timeline affects quality, and it is absent from most COAs.
Section 4: Product Specifications and Results
- Total nucleated cell count (TNC). Pre-processing total nucleated cells in the leukopak.
- PBMC yield post-processing. Total processed PBMCs recovered from the collection. Note that TNC and PBMC yield are different numbers — a COA that reports only TNC without processed PBMC yield is incomplete for most downstream applications.
- Viability (%). Method should be specified (trypan blue exclusion, 7-AAD, PI, etc.). For cryopreserved product, pre-freeze and post-thaw viability should both be present.
- CD4:CD8 ratio. Measured by flow cytometry. Critical for CAR-T programs; standard for any immunology application where T cell subset composition matters.
- T cell purity (CD3+%). Percent T cells in the PBMC fraction.
- CD14+ monocyte content (%). Monocyte contamination of the PBMC fraction. Above 40% is a documented CAR-T manufacturing failure predictor. This field is absent from many COAs.
- Granulocyte content (%). Granulocyte contamination should be below 3% for high-quality fresh leukapheresis product. This field should be present for all fresh material.
- NK cell content (CD3-CD56+ %). For NK cell therapy programs, NK cell frequency in the starting material is a relevant parameter. Standard for suppliers that service NK programs.
- B cell content (CD19+ %).
Section 5: Processing and Storage
- Processing protocol reference. SOP number and version for the processing procedure used. For GMP material, this is required for traceability.
- Cryopreservation method and cryoprotectant. For cryopreserved product: cryoprotectant identity and concentration (typically 10% DMSO in HSA-containing media), controlled-rate freezing vs. isopropanol bath, storage temperature.
- Storage conditions at supplier facility. Temperature and duration of storage before shipment.
- Shipping conditions. Temperature-controlled shipping method (dry ice, liquid nitrogen vapor shipper, etc.) and temperature monitoring record for the shipment.
Section 6: Release Authorization
- Release criteria met/not met for each parameter. Pass/fail against specification for each release criterion should be explicitly stated. A COA that lists results without stating whether each result meets the specification requires the recipient to perform the comparison manually — and means failed parameters may not be visually obvious.
- Releasing QA authority name and signature. For GMP material, a named, qualified individual must sign the COA to authorize release. Anonymous release is not compliant with GMP documentation standards.
- Release date.
- Expiration date or use-by date.
GMP vs. RUO COA Standards
| Documentation Element | RUO COA | GMP COA |
|---|---|---|
| Unique lot number | Required | Required |
| Donor eligibility determination per 21 CFR 1271.75 | Not required | Required |
| Named QA release authority | Not required | Required |
| SOP reference for processing | Recommended | Required |
| Pass/fail statement per specification | Recommended | Required |
| Collection-to-processing time | Recommended | Required for time-sensitive products |
| Full infectious disease testing panel with dates | Summary acceptable | Full results with dates required |
| Chain-of-identity traceability to donor record | Via donor ID | Via donor ID with full traceability documentation in file |
What Most COAs Leave Out (And Why It Matters)
The three fields most commonly absent from leukopak COAs, despite being among the most informative for downstream applications:
Collection-to-processing time. This is the single most informative processing quality indicator on a COA, and most suppliers don’t include it. If the product was processed 4 hours post-collection, that’s relevant. If it was processed 22 hours post-collection, that’s also relevant — in a different direction. Without this field, a recipient cannot assess whether the processing timeline was within the quality window for their application.
CD14+ monocyte content. Given the documented association between high monocyte content and CAR-T transduction failure, the absence of this field from COAs that are used for GMP cell therapy manufacturing is a gap that appears repeatedly in supplier qualification audits. A COA that doesn’t report monocyte content cannot be used to assess the CD14+ contamination risk before manufacturing.
CD4:CD8 ratio. For any application involving T cells — immunology research, CAR-T manufacturing, TCR therapy, Treg programs — the CD4:CD8 ratio is a primary characterization parameter. Its absence from a COA is either a signal that the supplier doesn’t measure it or that they measure it but don’t consider it a release parameter. Either way, it should be there.
OrganaBio’s Standard COA Fields
OrganaBio’s COA for leukopak and processed PBMC products includes all the fields described above as standard — including collection-to-processing time, CD14+ monocyte content, CD4:CD8 ratio, granulocyte contamination, and HLA typing. For GMP-grade material, the COA includes named QA release authorization, donor eligibility determination documentation, SOP references, and explicit pass/fail statements for each release criterion.
COA documentation packages for IND submission are available and formatted to meet FDA CMC expectations for starting material documentation.
If Your Current Supplier’s COA Is Missing Fields
If your current supplier’s COA doesn’t include collection-to-processing time, CD14+ monocyte content, or CD4:CD8 ratio, you have three options: request those fields as custom characterization (which adds cost and may add lead time), accept the documentation gap (with the associated quality risk), or evaluate suppliers whose standard COA already includes what you need.
For programs approaching IND submission, the second option is not available — the CMC will need the documentation that the starting material meets the specifications you’ve defined. Starting that documentation gap conversation before the IND filing deadline is considerably better than starting it during the FDA review cycle.
To discuss OrganaBio’s COA standards and documentation packages for cell therapy starting material, contact our team.
Frequently Asked Questions
What parameters should appear on a leukopak COA beyond viability and cell count?
A complete leukopak COA includes: granulocyte percentage (acceptably below 3%), PBMC yield and purity, T cell subset breakdown (CD3, CD4, CD8, CD56 at minimum), HLA typing data (ideally 6-digit NGS), infectious disease screening panel results (anti-HIV, HBsAg, anti-HCV, HTLV, anti-CMV, RPR, WNV as a minimum), ABO/Rh type, collection date, processing date, processing facility, and a unique traceable lot number. For GMP-grade material, the COA should also reference the manufacturing batch record.
What is the difference between an RUO leukopak COA and a GMP leukopak COA?
An RUO COA documents product identity and release testing sufficient for research use — typically viability, cell count, and infectious disease screening. A GMP COA documents release against a formally validated specification set, references the batch record and QC testing, includes documentation that each test was performed by a qualified analyst, and is part of the regulatory documentation package that follows the product through clinical use. GMP COAs must be audit-ready and traceable under 21 CFR Part 1271.
Does a leukopak COA need to include HLA typing data?
For allogeneic cell therapy applications and immunological research requiring donor matching, yes. HLA typing should appear on the COA for any leukopak used in applications where donor-recipient compatibility or longitudinal donor recallability matters. For basic T cell research or gene therapy starting material, HLA data is valuable but not always required at the COA level — it can be supplied as supplementary documentation. OrganaBio performs 6-digit NGS HLA typing on all qualified donors.
How do I use COA data across batches to predict downstream assay performance?
Track CD4:CD8 ratio, granulocyte percentage, and T cell memory subset distribution across lots. When you observe batch-to-batch assay variability, correlate it against these COA parameters. Over time you will identify which variables most strongly predict your specific assay outcomes — this allows you to tighten procurement specifications to exclude lots likely to underperform before they enter your workflow, rather than discovering the problem after the assay runs.
What infectious disease markers must be on a leukopak COA for clinical trial starting material?
FDA regulations under 21 CFR 1271.85 require testing for HIV-1, HIV-2, HBV (surface antigen), HCV, HTLV-I/II, Treponema pallidum (RPR), West Nile Virus, and Cytomegalovirus (CMV) as relevant communicable disease agents. Testing must be performed using FDA-licensed or approved tests. Test results must appear in the donor eligibility determination and be documented in the batch record associated with the COA.
Source from OrganaBio
FDA-registered. ISO 7 cGMP. Ships anywhere in the US.
Request Sample COAView LeukoPAK-FRSH
